<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234129</url>
  </required_header>
  <id_info>
    <org_study_id>kitty1</org_study_id>
    <secondary_id>kitty2</secondary_id>
    <nct_id>NCT01234129</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma</brief_title>
  <official_title>Results of Phase III Study to Assess if Zoledronic Acid Have Antumor Activity in Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Mexicano del Seguro Social</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess if the use of zoledronic acid can improve outcome in patients with multiple myeloma
      whose are treated with cytoreductive therapy and stem cell transplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free disease and overall toxicity in myeloma multiple</measure>
    <time_frame>3 years</time_frame>
    <description>In patients treated with cytoreductive therapy following by stem cell transplant and that received zoledronic acid by 2 years,they were evaluable for assess antitumor effect of zoledronic acid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>skeletal event</measure>
    <time_frame>3 years</time_frame>
    <description>evaluate the number of skeletal events in patients with multiple myeloma that received zoledronic acid</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">320</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>zoledronic acid or not zoledronic acid</arm_group_label>
    <description>patients with multiple myeloma will be treated with cytoreductive therapy following by zoledronic acid or not.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zoledronic acid or not zoledronic acid</arm_group_label>
    <description>patients with multiple myeloma will be treated with cytoreductive therapy following by stem cell transplant and did not received zoledronic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zoledronic acid</arm_group_label>
    <description>Patients with multiple treated with cytoreductive therapy following by stem cell transplant will be planned to received zoledronic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years</description>
    <arm_group_label>zoledronic acid or not zoledronic acid</arm_group_label>
    <arm_group_label>zoledronic acid</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with multiple myeloma previously untreated
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of multiple myeloma No previous treatment Symptomatic High risk (ISS) or stage
        III ( Durie-Salmon) No severe comorbidities -

        Exclusion Criteria:

        Pregnancy HIV + Refuse treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agustin Aviles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tertiary reference oncology center</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06725</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>November 3, 2010</last_update_submitted>
  <last_update_submitted_qc>November 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Agustin Aviles, Senior Researcher</name_title>
    <organization>Mexican Institute of Social Security</organization>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>stem cell transplant</keyword>
  <keyword>zoledronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

